Market Overview - On January 26, the A-share market experienced fluctuations, with the Shenzhen Composite Index and the ChiNext Index opening high but closing lower, both dropping over 1% during the day. The Shanghai Composite Index fell by 0.09%, the Shenzhen Composite Index by 0.85%, and the ChiNext Index by 0.91%. The total market turnover reached 3.28 trillion yuan, an increase of 162.5 billion yuan compared to the previous trading day, with over 3,700 stocks declining [1]. Precious Metals Sector - The precious metals sector led the market gains, with Sichuan Gold (001337) achieving four consecutive trading limits in eight days. Other stocks such as Xiaocheng Technology (300139), Hunan Gold (002155), and Shengda Resources (000603) also hit the daily limit, while Zijin Mining (601899) reached a historical high [1]. - On January 26, spot gold prices surpassed $5,100 per ounce, peaking at $5,110.26 per ounce. Silver prices also surged, with spot silver reaching a high of $109.453 per ounce, marking an increase of over 51% in just 17 trading days [3]. Investment Demand and Market Trends - The rising gold prices have significantly boosted market demand for gold investment and reserves, leading to a surge in bank safe deposit box rentals. For instance, at the Shenzhen branch of China Merchants Bank, all 8,000 safe deposit boxes are fully rented, with 500 to 600 customers waiting to rent a box. Given the annual turnover of only 20 to 30 boxes, new customers may have to wait 5 to 6 years [3]. - The A-share flu vaccine sector also showed strength, with stocks like Da'an Gene (002030), Hualan Biological (301207), and Zhijiang Biology hitting the daily limit, while Yongshun Biological surged over 27% [3]. Other Sector Movements - The oil and gas sector saw continued strength, with China National Offshore Oil Corporation (600938) reaching a historical high, and other companies like Zhongjie Oil and China Petroleum rising over 5% [6]. - The Tencent Cloud concept experienced localized movements, with stocks like Qunxing Toys (002575) hitting the daily limit and others like Ruijie Networks (301165) rising over 10% following Tencent's announcement of a new AI assistant app [7].

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with notable increases such as Kanglaweishi up over 20% and several others reaching the daily limit of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has prompted a response from local authorities, with nearly a hundred individuals under home quarantine due to the high mortality rate of up to 75% and the absence of a vaccine [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [1] Group 2 - Historical context indicates that Nipah virus outbreaks have previously occurred in Malaysia, Singapore, India, Bangladesh, and the Philippines, resulting in significant fatalities and the culling of millions of pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission rate through contaminated food or direct human-to-human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days, and there are currently no specific vaccines or effective treatments available [2] Group 3 - The stock performance of various biopharmaceutical companies shows substantial year-to-date gains, with Kanglaweishi at 45.10%, Maike Biological at 26.90%, and Kaipu Biological at 34.76% [3] - Other companies such as Zhijiang Biological and Jindike also reported significant increases, with year-to-date growth rates of 26.67% and 18.44% respectively [3] - The overall market trend indicates a strong investor interest in biopharmaceutical stocks amid the health crisis related to the Nipah virus outbreak [1][3]

据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最长 可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 | 代码 | 名称 | 张唱 | 总金额 | 总市值 | 现价 | | --- | --- | --- | --- | --- | --- | | 300463 | 迈克生物 | +20.03% | 7666.6 | 85.86 Z | 14.20 | | 300638 | 凯普生物 | +20.03% | 3.36 Z | 46.87 G | 7.25 | | 688317 | 之江生物 | +20.01% | 3.20 乙 | 49.10 Z | 25.55 | | 301207 | 华兰疫苗 | +20.00% | 5.75 G | 140.3 Z | 23.34 | | 688670 | 金 ...

据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 据央视新闻，近期，印度东部的西孟加拉邦出现尼帕病毒感染病例，目前已有5例确诊病例，其中包括 医护人员。据悉，近100人被要求居家隔离，感染者正在该邦首府加尔各答及周边医院接受治疗，其中 一名患者病情危重。 据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最 长可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 1月26日，流感板块午后拉升，截至发稿，迈克生物、凯普生物、之江生物、华兰疫苗20%涨停，达 安基因、特一药业、鲁抗医药、科华生物等涨停，智飞生物、万孚生物、康希诺、沃森生物等涨超 10%。 ...

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]

Group 1 - The A-share influenza vaccine sector is experiencing a strong performance, with companies such as Da'an Gene, Hualan Biological Engineering, and Zhijiang Biological reaching their daily limit up [1] - Yongshun Biological has seen an increase of over 10%, indicating positive market sentiment towards the sector [1] - Other companies in the sector, including Dongfang Biological, Biological Shares, Zhongsheng Pharmaceutical, Yiling Pharmaceutical, and Rhine Biological, are also witnessing gains [1]

达安基因：公司此前表示已有尼帕病毒核酸检测的科研技术储备。 圣湘生物：此前表示推进亨尼帕病毒检测试剂的研发工作。 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 据环球时报报道，近日，印度西孟加拉邦暴发尼帕病毒疫情。 另据人民网，鉴于近期尼帕病毒（Nipah Virus）在印度出现传播风险，泰国清迈国际机场已全面升级对 国际入境旅客的健康筛查措施，以加强疫情监测与防控，防范病毒输入风险。 而智通财经介绍，世界卫生组织将尼帕病毒列为一种致命的人畜共患病毒，主要由果蝠携带。该病毒可 通过被污染的食物传播给人类，或直接人传人，死亡率在40%到75%之间。据世卫组织介绍，这种病毒 从感染到出现症状的潜伏期一般为4天至14天，最长可达45天。目前尚无专门针对尼帕病毒的疫苗和有 效疗法。 公司方面，据上市公司互动平台表示， ...

证券日报网讯 1月22日，达安基因在互动平台回答投资者提问时表示，公司仅提供每月月末股东人数， 截至2025年12月31日，公司股东总户数约为13.2万户。 （文章来源：证券日报） ...

证券日报网讯 1月16日，达安基因（002030）在互动平台回答投资者提问时表示，公司高度重视历史应 收账款的回款工作，2025年以来公司持续加强应收账款的全流程管理，通过组建专班、指定专人，综合 采取协商、法律等方式积极推动回款，总体回款情况良好。涉及财务的具体数据请以公司在指定媒体披 露的定期报告为准。公司将继续依法合规、多措并举推进应收账款管理，持续优化资产质量，维护公司 及全体股东的利益。 ...

（编辑 王雪儿） 证券日报网讯 1月14日，达安基因在互动平台回答投资者提问时表示，公司历来披露全资及控股子公司 获得三类医疗器械注册证的情况。广州赛隽生物科技有限公司是公司控股子公司广州市达瑞生物技术股 份有限公司的合营企业，未纳入公司合并报表范围。 ...